S

Shattuck Labs
D

STTK

1.01000
USD
-0.10
(-9.01%)
مغلق
حجم التداول
0
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
48,204,542
الأخبار

العنوان: Shattuck Labs

القطاع: Healthcare
الصناعة: Biotechnology
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.